GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Capex-to-Revenue

Y-Biologics (XKRX:338840) Capex-to-Revenue : 0.58 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Y-Biologics's Capital Expenditure for the three months ended in Mar. 2024 was ₩-664.58 Mil. Its Revenue for the three months ended in Mar. 2024 was ₩1,142.67 Mil.

Hence, Y-Biologics's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.58.


Y-Biologics Capex-to-Revenue Historical Data

The historical data trend for Y-Biologics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Capex-to-Revenue Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial 1.86 4.44 0.14 1.56 0.26

Y-Biologics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only 0.02 0.05 0.04 0.14 0.58

Competitive Comparison of Y-Biologics's Capex-to-Revenue

For the Biotechnology subindustry, Y-Biologics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Y-Biologics's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-Biologics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Y-Biologics's Capex-to-Revenue falls into.



Y-Biologics Capex-to-Revenue Calculation

Y-Biologics's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1097.308) / 4150.558
=0.26

Y-Biologics's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-664.579) / 1142.665
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Y-Biologics  (XKRX:338840) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Y-Biologics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-Biologics (XKRX:338840) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR
Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines